In the original article, there was a mistake in Table 1 and in the Section Results, Patients’ Clinical Characteristics as published. “There were errors in the values for the ‘Ambrisentan dose’ as it was reported that one hundred and twenty-eight patients (88.3%) were receiving 10 mg once per day, whereas seventeen patients (11.7%) were receiving 5 mg once daily. This was corrected to sixty-one patients (42.1%) were receiving 10 mg once per day, and eighty-four patients (57.9%) were receiving 5 mg once daily.” The corrected Table 1 appears below and the text in the Section Results, Patients’ Clinical Characteristics has been updated.
TABLE 1
| Characteristic | All patients (N = 145) |
|---|---|
| Age, yearsa | 32.0 (26.0, 42.0) |
| Sex, n (%) | |
| Female | 108 (74.5) |
| Male | 37 (25.5) |
| Duration of ambrisentan treatment before transition, yearsa | 1.5 (1.0, 2.9) |
| mPAP, mmHgb,c | 61.4 ± 18.6 |
| PVR, Wooda,c | 14.4 (8.0, 22.1) |
| mRAP, mmHgb,c | 10.0 ± 5.8 |
| mRVP, mmHgb,c | 41.7 ± 12.4 |
| Etiology of PAH, n (%) | |
| Idiopathic | 32 (22.1) |
| Drug or toxin-induced | 4 (2.8) |
| Associated with connective tissue disease | 21 (14.4) |
| Associated with congenital heart disease | 88 (60.7) |
| Ambrisentan dose, mg, QD | |
| 5 n (%) | 84 (57.9) |
| 10 n (%) | 61 (42.1) |
| WHO FC, n (%) | |
| II | 85 (58.6) |
| III | 60 (41.4) |
| BMI (kg/m2) b | 21.0 ± 3.2 |
| PAH medications in addition to taking ambrisentan, n (%) | |
| Monotherapy | 18 (12.4) |
| PDE-5i | 122 (84.1) |
| Riociguat | 4 (2.8) |
| Riociguat and PDE-5i | 1 (0.7) |
Baseline characteristics.
Data are described as medians and interquartile ranges (non-normal distribution).
Data are described as means and standard deviations (normal or approximately normal distribution).
Historical data from the most recent right heart catheterization before enrollment.
mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; mRAP, mean right atrial pressure; mRVP, mean right ventricular pressure; QD, once per day; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class; BMI, body mass index; PDE-5i, phosphodiesterase type 5 inhibitor.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
pulmonary arterial hypertension, macitentan, ambrisentan, endothelin receptor antagonist, real-word study
Citation
Chen Y, Luo J, Chen J, Kotlyar E, Li Z, Chen W and Li J (2022) Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study. Front. Pharmacol. 13:891907. doi: 10.3389/fphar.2022.891907
Received
08 March 2022
Accepted
15 March 2022
Published
11 April 2022
Volume
13 - 2022
Edited and reviewed by
Kevin Lu, University of South Carolina, United States
Updates
Copyright
© 2022 Chen, Luo, Chen, Kotlyar, Li, Chen and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jiang Li, lijiangcs@csu.edu.cn
This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.